What are the adverse side effects of fluoroquinolones?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adverse Side Effects of Fluoroquinolones

Fluoroquinolones cause a spectrum of serious, potentially disabling musculoskeletal, neurologic, cardiovascular, and dermatologic adverse effects that prompted FDA black box warnings in 2008 and EU-wide restrictions in 2019.

Musculoskeletal Complications

Tendon Disorders (Most Common and Serious)

The Achilles tendon is affected in 90% of fluoroquinolone-associated tendinopathies, with symptoms typically appearing within 1 week of exposure (median 6 days, though can occur 2 hours to 6 months after exposure). 1

Risk quantification:

  • Current use increases Achilles tendon rupture risk 4.1-fold (odds ratio 4.1,95% CI 1.8-9.6) 1
  • Overall tendon disorder risk increases 1.7-fold (odds ratio 1.7,95% CI 1.4-2.0) 1
  • Absolute risk: 1 Achilles rupture per 5,958 patients treated 1
  • In patients >60 years: 1 rupture per 1,638 patients 1
  • With concomitant corticosteroids: 1 rupture per 979 patients (odds ratio 43.2,95% CI 5.5-341.1) 1

Other affected tendons include: patellar, rotator cuff, common flexor/extensor origins at elbow, biceps, and plantar foot tendons 1

Clinical presentation: Pain is the primary symptom, with 26% of patients reporting persistent pain and disability even after discontinuation 1

High-Risk Populations for Tendinopathy

The following factors substantially increase risk 1:

  • Age >60 years (4-fold increased risk)
  • Concurrent corticosteroid use (43-fold increased risk for Achilles rupture when combined)
  • Active participation in sports (50% of athletic patients developed symptoms during sports activity)
  • Organ transplantation
  • End-stage renal disease/hemodialysis
  • Rheumatoid arthritis, systemic lupus erythematosus
  • Diabetes mellitus
  • Magnesium deficiency

Neurologic Adverse Events

CNS effects include: 2, 1

  • Dizziness (most common neurologic complaint)
  • Peripheral neuropathy (potentially permanent and disabling)
  • Nervousness and insomnia
  • Convulsions (particularly with lomefloxacin due to GABA antagonism)
  • Psychoses
  • Somnolence

The neurologic effects are related to GABA antagonism and NMDA receptor binding, with risk increased by concomitant NSAID use. 3

Cardiovascular Complications

QTc interval prolongation is a class effect, with sparfloxacin specifically linked to cardiac arrhythmias. 3 While clinically significant cardiac events remain rare with newer fluoroquinolones, patients receiving other QT-prolonging medications require careful monitoring. 4

Aortic aneurysm and dissection represent emerging serious cardiovascular risks identified in post-marketing surveillance 5, 6

Dermatologic Reactions

Phototoxicity varies significantly by agent:

  • 8-halogenated compounds (particularly lomefloxacin and sparfloxacin) cause significantly more phototoxicity through generation of toxic free oxygen species under UVA exposure 3, 4
  • Patients with cystic fibrosis are predisposed to photoreactions 3
  • Murine photocarcinogenicity demonstrated with lomefloxacin, though not reported in humans 3

Hepatotoxicity

Mild transaminase elevations are a class effect, typically asymptomatic. However, post-marketing surveillance revealed significant hepatotoxicity with trovafloxacin (now withdrawn), with severity comparable to flucloxacillin and amoxicillin-clavulanic acid 3

Cartilage and Bone Effects

Arthralgia, impaired fracture healing, and cartilage lesions occur through mechanisms involving collagen degradation and chondrocyte toxicity 1, 5

Muscle Complications

Myalgia and rhabdomyolysis have been reported, though less common than tendon disorders 1

Pediatric Considerations

In pediatric populations, long-term follow-up studies showed:

  • Musculoskeletal adverse events at 5 years were actually slightly higher in comparator groups (4%) versus levofloxacin (2%) 2
  • Growth characteristics remained similar between treatment groups 2
  • However, restrictions on pediatric use persist due to animal studies showing cartilage damage, though extensive human data from Japan and developing countries have not confirmed articular effects 3

Incidence and Reporting

Overall adverse event rates:

  • 8.5% of fluoroquinolone users develop ADRs versus 4.1% with other antibiotics 7
  • Levofloxacin (particularly 750mg dose) causes the highest number of reported ADRs 7
  • Tendon disorder frequency: 4-20 per 100,000 prescriptions (likely underreported) 1

Critical Clinical Pitfalls

  1. Never combine fluoroquinolones with systemic corticosteroids in patients >60 years - this creates a 43-fold increased risk of Achilles rupture 1

  2. Symptoms can appear rapidly (within hours) or delayed (up to 6 months post-treatment) - maintain vigilance throughout and after treatment 1

  3. Discontinue immediately upon first sign of tendon pain, swelling, or inflammation - 26% of patients have persistent disability despite stopping the drug 1

  4. Athletes require special caution - 50% of active patients developed tendon problems during sports participation 1

  5. The absolute risk remains low despite elevated relative risk - use this for informed consent discussions 1

Mechanism of Toxicity

Fluoroquinolones cause musculoskeletal damage through multiple pathways 1:

  • Chelation of magnesium and other divalent cations, disrupting cell signaling
  • Direct toxic effects on collagen (types I and III), elastin, and fibronectin
  • Reduction in β1 integrin expression affecting cell-matrix adhesion
  • Generation of reactive oxygen species
  • Stimulation of matrix metalloproteinases causing tissue breakdown

Magnesium supplementation shows promise in reducing chondrotoxicity in animal models, though human data remain limited. 1

References

Research

Safety of fluoroquinolones.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2024

Research

Fluoroquinolone antibiotics and adverse events.

Australian prescriber, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.